Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling TJ Jr, Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, Verhamme P, Cohen AT, Beyer-Westendorf J, Gibson CM, Lopez-Sendon J, Crowther M, Shoamanesh A, Coppens M, Schmidt J, Albaladejo P, Connolly SJ; ANNEXA-4 Investigators. Milling TJ Jr, et al. Among authors: coppens m. Circulation. 2023 Mar 28;147(13):1026-1038. doi: 10.1161/CIRCULATIONAHA.121.057844. Epub 2023 Feb 20. Circulation. 2023. PMID: 36802876 Free article. Clinical Trial.
Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study - cohort-based randomised controlled trial.
Burggraaf-van Delft JLI, van Rein N, Bemelmans RHH, van den Berg JK, Bruggeman CY, Cloos-van Balen M, Coppens M, Eefting M, Ende-Verhaar Y, van Es N, van Guldener C, de Jong WK, Kleijwegt F, Koster T, Kroon C, Kuipers S, Leentjens J, Luijten D, Mairuhu ATA, Meijer K, van de Ree MA, Roos R, Schrover I, Swart-Heikens J, van der Velden AWG, van den Akker-van Marle EM, le Cessie S, Geersing GJ, Middeldorp S, Huisman MV, Klok FA, Cannegieter SC; L-TRRiP investigators. Burggraaf-van Delft JLI, et al. Among authors: coppens m. BMJ Open. 2024 Mar 23;14(3):e078676. doi: 10.1136/bmjopen-2023-078676. BMJ Open. 2024. PMID: 38521524 Free PMC article.
Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH, Mathôt RAA; OPTI‐CLOT study group. Preijers T, et al. J Thromb Haemost. 2018 Nov;16(11):2196-2207. doi: 10.1111/jth.14292. Epub 2018 Oct 28. J Thromb Haemost. 2018. PMID: 30394056 Free article.
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
Coppens M, Pipe SW, Miesbach W, Astermark J, Recht M, van der Valk P, Ewenstein B, Pinachyan K, Galante N, Le Quellec S, Monahan PE, Leebeek FWG; HOPE-B Investigators. Coppens M, et al. Lancet Haematol. 2024 Apr;11(4):e265-e275. doi: 10.1016/S2352-3026(24)00006-1. Epub 2024 Mar 1. Lancet Haematol. 2024. PMID: 38437857 Clinical Trial.
Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.
Zwagemaker AF, Kloosterman FR, Gouw SC, Boyce S, Brons P, Cnossen MH, Collins PW, Eikenboom J, Hay C, Hengeveld RCC, Jackson S, Klopper-Tol CAM, Kruip MJHA, Gorkom BL, Male C, Nieuwenhuizen L, Shapiro S, Fijnvandraat K, Coppens M; DYNAMO study group. Zwagemaker AF, et al. Among authors: coppens m. J Thromb Haemost. 2023 Apr;21(4):850-861. doi: 10.1016/j.jtha.2022.11.040. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696222 Free article.
Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B.
Goedhart TMHJ, Bukkems LH, Zwagemaker AF, Coppens M, Fijnvandraat K, Schols SEM, Schutgens REG, Eikenboom J, Heubel-Moenen FCJI, Ypma PF, Nieuwenhuizen L, Meijer K, Leebeek FWG, Mathôt RAA, Cnossen MH. Goedhart TMHJ, et al. Among authors: coppens m. Res Pract Thromb Haemost. 2024 Mar 28;8(3):102397. doi: 10.1016/j.rpth.2024.102397. eCollection 2024 Mar. Res Pract Thromb Haemost. 2024. PMID: 38689619 Free PMC article.
In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype.
Verhagen MJA, van Heerde WL, van der Bom JG, Beckers EAM, Blijlevens NMA, Coppens M, Gouw SC, Jansen JH, Leebeek FWG, van Vulpen LFD, Meijer D, Schols SEM. Verhagen MJA, et al. Among authors: coppens m. Res Pract Thromb Haemost. 2023 Feb 1;7(2):100062. doi: 10.1016/j.rpth.2023.100062. eCollection 2023 Feb. Res Pract Thromb Haemost. 2023. PMID: 36865907 Free PMC article.
The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A.
Oomen I, Verhagen M, Miranda M, Allacher P, Beckers EAM, Blijlevens NMA, van der Bom JG, Coppens M, Driessens M, Eikenboom JCJ, Fijnvandraat K, Hassan S, van Heerde WL, Hooimeijer HL, Jansen JH, Kaijen P, Leebeek FWG, Meijer D, Paul H, Rijpma SR, Rosendaal FR, Smit C, van Vulpen LFD, Voorberg J, Schols SEM, Gouw SC. Oomen I, et al. Among authors: coppens m. Front Immunol. 2024 Feb 22;15:1355813. doi: 10.3389/fimmu.2024.1355813. eCollection 2024. Front Immunol. 2024. PMID: 38455035 Free PMC article.
305 results